

RESULTS: The minimum percent of the amount of fat aspirated of body weight during the procedure was 7% and the maximum was 22%. Incidence of anemia was 8% of cases. The Results were evaluated by patient's satisfaction score (from 0 to 30). 41 patients reported a score of (25–30), 5 reported (20–25), 2 reported (15–20) and 2 reported (10–15). The latter 4 patients had minor complications like Seroma and excessive fatigue and tiredness.

CONCLUSION: Mega liposuction is a demanding procedure by both the surgeon and the patient to achieve the best results and contour. With adequate planning, patient selection and adequate setting, Mega-liposuction can be very pleasing and a safe procedure performed with up to 25 liters of fluid aspirated.

REFERENCES:

1. Iverson RE, Lynch MD, and the ASPS Committee on Patient Safety. Practice advisory on liposuction. *Plast Reconstr Surg*. 2004;113:1478–1485.
2. Albin R, de Campo T. Large-volume liposuction in 181 patients. *Aesthetic Plast Surg*. 1999;23:5–15.
3. Commons GW, Halperin B, Chang CC. Large-volume liposuction: a review of 631 consecutive cases over 12 years. *Plast Reconstr Surg*. 2001;108:1753–1763.
4. Klassen AF, Cano SJ, Alderman A, Soldin M, Thoma A, Robson S, et al. The BODY-Q: A Patient-Reported Outcome Instrument for Weight Loss and Body Contouring Treatments. *Plast Reconstr Surg Glob Open* [Internet]. 2016 Apr 13 [cited 2017 Nov 10];4(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859238/>
5. Cárdenas-Camarena L, Tobar-Losada A, Lacouture AM. Large-volume circumferential liposuction with tumescent technique: a sure and viable procedure. *Plast Reconstr Surg*. 1999 Nov;104(6):1887–99.
6. Dhami LD, Agarwal M. Safe total corporal contouring with large-volume liposuction for the obese patient. *Aesthetic Plast Surg*. 2006 Sep-Oct;30(5):574–88.

BREAST SESSION 1

Deferoxamine Increases Breast Cancer Radiosensitivity

Presenter: Kavitha Ranganathan, MD

Co-Authors: Jeremy V. Lynn, BS; Kevin M. Urlaub, BS; Alexis Donneys, MS, MD;

Noah S. Nelson, BS, MPH; Chitra Subramanian, MBA, PhD; Mark S. Cohen, MD, FACS; Steven R. Buchman, MD

Affiliation: University of Michigan, Ann Arbor, MI

OBJECTIVE: Radiotherapy reduces the risk of breast cancer recurrence by destroying residual cancer cells post-surgery. The detrimental effect of radiation on surrounding tissues, however, significantly increases complications including reconstructive failure during both autologous and implant-based breast reconstruction.¹ Pharmacologic treatments aimed at mitigating radiation-induced injury have the potential to improve outcomes among these patients. Specifically, recent studies in our laboratory suggest deferoxamine (DFO) is capable of reducing skin ulceration and collagen fibril disorganization following radiation. What remains unclear, however, is whether breast cancer cells are concomitantly protected, a factor that would worsen cancer-specific outcomes among patients undergoing reconstruction. The purpose of this study is to determine the impact of DFO delivered in combination with XRT on breast cancer cell proliferation to ensure that tumor growth will not be concomitantly enhanced given the obvious improvements in skin viability resulting from DFO treatment.

METHODS: Two triple-negative breast cancer cell lines, MDA-MB-231 and MDA-MB-468, were obtained from the University of Michigan Comprehensive Cancer Center and grown in culture. The dose-dependent effect of XRT (0, 5, and 10Gy) and DFO (0, 25, 50, 75, and 100 μ M) on proliferation of each cell line was determined via hemocytometer. Then, the radiosensitivity of these cell lines was determined at 10Gy of XRT and increasing doses of DFO. All three experiments were replicated via an MTS assay, a colorimetric assay for assessing cell metabolic activity, to fortify the results. All experiments were performed in triplicate. Statistical analysis was performed at $p < 0.05$ significance using SPSS.

RESULTS: Cell number significantly decreased in both MDA-MB-231 (171×10^4 to 86×10^4 , $p = 0.00$) and MDA-MB-468 (145×10^4 to 31×10^4 , $p = 0.00$) cells following exposure to 5Gy of XRT. Surprisingly, cell number also significantly decreased in response to 25 μ M DFO (MDA-MB-231: 171×10^4 to 34×10^4 , $p = 0.00$; MDA-MB-468: 145×10^4 to 13×10^4 , $p = 0.04$). The sensitivity of both triple-negative breast cancer cell lines to 10Gy of XRT increased